Join us on the latest episode! Our Guest: Simon Allen, Former CEO, Anebulo PharmaceuticalsWhat you'll get out of this episode:Journey from biochemistry to sell-side biotech business development.Current treatment landscape for ACI and the limitations therein.Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload.Impact of synthetic cannabinoids and the silent peril they pose.Upcoming milestones: Finalization of Phase 2 data and optimistic outlook towards FDA outcomes.*Since the recording of this episode Simon has moved onto new endeavors*To learn more about Anebulo Pharmaceuticals: https://www.anebulo.com/Our sponsors for this episode are:Sage Growth Partners https://sage-growth.com/

Ver todos los episodios